Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
5 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Atara Biotherapeutics, Inc.’s names, not what it holds today.
Patents granted
5
5 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
10
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Atara Biotherapeutics, Inc. its own name
named as the applicant on its applications, in US
8 publishedAtara Biotherapeutics, Inc. its own name
US, as the owner printed on each patent
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 12, 2025 | 12,383,572 | Administration of an anti-activin-a compound to a subject | Pharmaceuticals | Atara Biotherapeutics, Inc. |
| Mar 12, 2024 | 11,925,663 | Methods of managing tumor flare in adoptive immunotherapy | Pharmaceuticals | Atara Biotherapeutics, Inc. |
| Jan 3, 2023 | 11,541,070 | Administration of an anti-activin-A compound to a subject | Pharmaceuticals | Atara Biotherapeutics, Inc. |
| Aug 6, 2013 | 8,501,678 | Variant activin receptor polypeptides and uses thereof | Pharmaceuticals | Atara Biotherapeutics, Inc. |
| Apr 2, 2013 | 8,410,043 | Stabilized activin IIB receptor polypeptides and uses thereof | Pharmaceuticals | Atara Biotherapeutics, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 28, 2025 | 2025/0270272 | METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS | Biotechnology | Atara Biotherapeutics, Inc. |
| Jul 10, 2025 | 2025/0226072 | SYSTEMS AND METHODS FOR DISTRIBUTING CELL THERAPIES | Medical technology | Atara Biotherapeutics, Inc. |
| Jun 29, 2023 | 2023/0201231 | ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT | Pharmaceuticals | Atara Biotherapeutics, Inc. · patent 12,383,572 granted from it |
| Jan 12, 2023 | 2023/0010255 | CAR T CELLS THAT TARGET ASPERGILLUS-ASSOCIATED ANTIGENS | Biotechnology | Atara Biotherapeutics, Inc. |
| Nov 3, 2022 | 2022/0348649 | ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS | Biotechnology | Atara Biotherapeutics, Inc. |
| Dec 23, 2021 | 2021/0393683 | METHODS OF MANAGING TUMOR FLARE IN ADOPTIVE IMMUNOTHERAPY | Pharmaceuticals | Atara Biotherapeutics, Inc. · patent 11,925,663 granted from it |
| Sep 30, 2021 | 2021/0301255 | METHODS FOR EXPANDING ANTIGEN-SPECIFIC CAR-T CELLS, COMPOSITIONS AND USES RELATED THERETO | Biotechnology | Atara Biotherapeutics, Inc. |
| Nov 5, 2020 | 2020/0350049 | SYSTEMS AND METHODS FOR DISTRIBUTING CELL THERAPIES | Medical technology | Atara Biotherapeutics, Inc. |
| Jun 25, 2020 | 2020/0197439 | IMMUNOTHERAPY FOR POLYOMAVIRUSES | Pharmaceuticals | Atara Biotherapeutics, Inc. |
| Nov 21, 2019 | 2019/0350981 | METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS | Biotechnology | Atara Biotherapeutics, Inc. |
What it applied for, 2024 to 2025: Medical technology 1 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.